B2RLaw advises biotech company Ambulero on fundraising

B2RLaw has advised Ambulero, Inc., a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease on funding of up to USD 5.5 million received from from Orphinic Scientific.

As part of the investment, and with the help of B2RLaw, Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp. z o.o.) that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. The disease is rare in the US but more common in certain parts of Central and Eastern Europe.

Ambulero is a biotechnology company dedicated to advancing a platform of cell and gene therapies to treat serious vascular diseases. The company is a 2019 spin-out of the University of Miami co-founded by Robert L. Buchanan, Randy Berholtz, Omaida C. Velazquez and Jun Zhao-Liu. It holds an exclusive license from the University of Miami to develop and commercialize research from the laboratories of Drs. Omaida C. Velazquez and Jun Zhao-Liu.

With offices in Palo Alto, California and Warsaw, Poland, Orphinic Scientific is an innovative drug development and investment company focused on mid-market opportunities and orphan drugs in late preclinical research and Phase 1 or 2.

B2RLaw’s team was led by Partner Szymon Syp and included Senior Associate Iga Wojtczak – Opala and Junior Associate Jakub Niemiec.

Szymon Syp advises, “We congratulate Ambulero and Orphinic Scientific on this transaction. Ambulero’s important work means that people that suffer from serious vascular disease (which at best, causes severe discomfort and at worst, can result in death) can live in comfort with the knowledge that innovative treatment is on the horizon. We wish Ambulero the best of luck on its future clinical testing”.